Reuters logo
BRIEF-Keryx Biopharmaceuticals Q3 loss per share $0.20
November 7, 2017 / 12:18 PM / 16 days ago

BRIEF-Keryx Biopharmaceuticals Q3 loss per share $0.20

Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc

* Keryx Biopharmaceuticals announces third quarter 2017 financial results

* Q3 loss per share $0.20

* Q3 revenue $15 million versus I/B/E/S view $17.9 million

* Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

* Keryx Biopharmaceuticals Inc- ‍cash and cash equivalents as of Sept 30, 2017 totaled $114.0 million compared to $111.8 million as of Dec 31, 2016​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below